This is a randomized, double-blind, placebo-controlled Phase 2 study evaluating oral
administration of CAD-1883 in the treatment of adults with a genotypic diagnosis of
Spinocerebellar Ataxia (SCA). This study offers the opportunity to understand the safety,
tolerability, and efficacy of CAD-1883 in the SCA patient population.